Visão geral da empresa
A clinical-stage biotechnology enterprise, Q32 Bio Inc., focuses on developing novel biologics designed to restore healthy immune balance for patients suffering from alopecia areata and other autoimmune and inflammatory conditions driven by pathological immune dysfunction. The company operates within the healthcare sector, specifically in the biotechnology industry, which implies a focus on high-risk, high-reward research and development with significant regulatory hurdles before product commercialization. Q32 Bio Inc. currently maintains a market capitalization of $82.51M, generates annual revenue of $53.74M, and employs 24 individuals to execute its business strategy. These financial figures indicate a company with a relatively small market cap relative to its reported revenue, suggesting a specialized niche operation where revenue generation may be concentrated in specific product lines or services while maintaining a lean organizational structure with a minimal workforce of 24 employees.
Saúde financeira
Q32 Bio Inc. reports a trailing twelve-month revenue of $53.74M, net income of $29.82M, and EBITDA of $17.29M. The substantial gap between the revenue figure and the net income reveals an extremely efficient cost structure, as the company converts more than half of its top-line revenue into profit, indicating minimal overhead or operational inefficiencies. The company reports free cash flow of $4.52M, which signifies a degree of financial flexibility allowing for potential reinvestment in research and development or operational scaling without immediate reliance on external capital markets. The company demonstrates robust profitability across three key metrics: a gross margin of 64.4%, an operating margin of 85.4%, and a profit margin of 55.5%, where each margin level indicates that the company retains a high percentage of revenue after accounting for cost of goods sold, operating expenses, and total expenses respectively. In terms of leverage, the company holds $48.30M in cash against $15.34M in debt, supported by a debt-to-equity ratio of 36.52, which presents a complex balance sheet picture requiring careful interpretation of how equity is calculated relative to debt obligations. The current ratio stands at 4.85, indicating a very strong short-term liquidity position where current assets significantly exceed current liabilities, ensuring the ability to meet obligations as they come due. Furthermore, the return on equity is 125.1% and the return on assets is 13.7%, revealing that management is highly effective at generating returns on shareholders' equity while maintaining a lower return on the total asset base, potentially due to the capital structure or asset intensity of the business model.
Avaliação de valorização
The valuation metrics for Q32 Bio Inc. show a trailing P/E ratio of 2.33 and a forward P/E of -1.05. The difference between these two ratios implies a significant divergence between current earnings performance and expected future earnings trajectory, suggesting that the market anticipates a material change in profitability or that future earnings expectations are currently negative or not yet realized. The price-to-book ratio is 1.73, which indicates that the market is pricing the company at a 73% premium over its book value, reflecting investor expectations of future growth or asset quality that exceeds the historical accounting value. Additional valuation context is provided by the price-to-sales ratio of 1.54 and an EV/EBITDA of 3.49, which suggest that the company is valued moderately relative to its revenue and earnings before interest, taxes, depreciation, and amortization, offering alternative perspectives on intrinsic value beyond the price-to-earnings multiple. Regarding trading range, the stock has a 52-week high of $8.04 and a 52-week low of $1.34, meaning the current price sits within a wide volatility band between these extremes. The beta value is recorded as -1.02, which explains that the stock price exhibits inverse volatility relative to the broader market, moving in the opposite direction with greater magnitude than the market average during periods of price fluctuation.
Growth & Income
The growth metrics for Q32 Bio Inc. indicate that revenue growth year-over-year is N/A and earnings growth year-over-year is N/A. Since specific growth rates are not available in the provided data, it is not possible to determine whether earnings are growing faster or slower than revenue at this time, leaving the trajectory of top-line and bottom-line expansion undefined in the current reporting period. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the company reinvests all of its earnings back into the business rather than distributing them to shareholders. The overall growth and income profile is characterized by a lack of current dividend income and unavailable year-over-year growth data, focusing the investor's attention on capital appreciation potential and the company's ability to generate cash flow for internal funding.